UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: IMGN |
| Industry | Biopharmaceuticals |
| Founded | 1981 |
| Headquarters | Waltham, Massachusetts, United States |
|
Number of employees
|
280 |
| Website | www |
ImmunoGen, Inc. (NASDAQ: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
Currently approved ADCs with ImmunoGen technology employ one of the company's maytansinoid cell-killing agents, either DM1 or DM4, or one of the company's DNA-acting IGN payloads.
ImmunoGen also developed isatuximab, a monoclonal antibody without linkage to a toxin.
ImmunoGen uses its ADC technology to develop its own product candidates. Products currently in clinical-stage development include:
The company also selectively outlicenses limited use of its technology to other companies. Companies licensing ImmunoGen's technology include Amgen, Bayer HealthCare, Biotest, Genentech/Roche, Eli Lilly, Novartis, Sanofi, and Takeda. Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and launched in a number of countries, including the US, where it is marketed by Genentech, a member of the Roche Group. In October 2015, the company disclosed that Kadcyla had failed to meet its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2-positive advanced gastric cancer.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q3 2022 | 2022-10-27 | Future report Set alerts | |
| Q2 2022 | 2022-07-29 | -0.24 | -0.24 |
| Q1 2022 | 2022-05-06 | -0.10 | -0.10 |
| Q4 2021 | 2022-02-25 | -0.17 | -0.17 |
| Q3 2021 | 2021-10-29 | -0.18 | -0.18 |
| Q2 2021 | 2021-07-30 | -0.15 | -0.15 |
| Q1 2021 | 2021-05-10 | -0.17 | -0.17 |
| Q4 2020 | 2021-02-12 | 0.16 | 0.16 |
| Q3 2020 | 2020-11-06 | 0.00 | 0.00 |
| Q2 2020 | 2020-07-31 | -0.14 | -0.14 |
| 2016-06-08 | Reiterated Rating | Cantor Fitzgerald | Hold | |
| 2016-06-06 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-05-19 | Reiterated Rating | RBC Capital | Sector Perform | $7.00 |
| 2016-05-19 | Reiterated Rating | Royal Bank Of Canada | Sector Perform | $7.00 |
| 2016-05-05 | Reiterated Rating | Morgan Stanley | Underweight | $9.00 to $5.00 |
| 2016-05-02 | Boost Price Target | Leerink Swann | Market Perform | $8.00 to $11.00 |
| 2016-04-30 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2016-04-29 | Reiterated Rating | Cowen and Company | Hold | $8.50 |
| 2016-04-29 | Downgrade | RBC Capital | Outperform to Sector Perform | $18.00 to $7.00 |
| 2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-02-04 | Reiterated Rating | Canaccord Genuity | Buy | $20.00 |
| 2016-02-01 | Lower Price Target | RBC Capital | Outperform | $19.00 to $18.00 |
| 2016-01-31 | Reiterated Rating | William Blair | Outperform | |
| 2016-01-29 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2015-12-03 | Reiterated Rating | Jefferies Group | Hold | $8.00 |
| 2015-11-25 | Upgrade | Jefferies Group | Hold to Buy | $8.00 to $16.00 |
| 2015-11-17 | Reiterated Rating | RBC Capital | Outperform | $19.00 |
| 2015-11-10 | Reiterated Rating | Oppenheimer | Buy | $24.00 |
| 2015-11-10 | Reiterated Rating | Oppenheimer Holdings Inc. | Buy | $24.00 |
| 2015-11-09 | Reiterated Rating | Canaccord Genuity | Buy | |
| 2015-10-28 | Lower Price Target | Leerink Swann | Market Perform | $15.00 to $14.00 |
| 2015-10-23 | Reiterated Rating | Canaccord Genuity | Buy | $20.00 |
| 2015-09-21 | Reiterated Rating | Oppenheimer | Buy | |
| 2015-09-21 | Reiterated Rating | RBC Capital | Outperform | $20.00 |
| 2015-09-21 | Reiterated Rating | Cantor Fitzgerald | Hold | $21.00 to $19.00 |
| 2015-09-21 | Reiterated Rating | Canaccord Genuity | Buy | $20.00 |
| 2015-09-21 | Downgrade | Morgan Stanley | Equal Weight to Underweight | $10.00 to $9.00 |
| 2015-08-03 | Downgrade | Cantor Fitzgerald | Buy to Hold | $22.00 to $21.00 |
| 2015-07-29 | Boost Price Target | Oppenheimer | Outperform | $13.00 to $24.00 |
| 2015-07-27 | Reiterated Rating | RBC Capital | Outperform | $15.00 to $20.00 |
| 2015-06-08 | Boost Price Target | Leerink Swann | Market Perform | $9.00 to $15.00 |
| 2015-06-02 | Reiterated Rating | RBC Capital | Outperform | $10.00 to $15.00 |
| 2015-06-01 | Reiterated Rating | Cantor Fitzgerald | Buy | $12.00 |
| 2015-06-01 | Reiterated Rating | Oppenheimer | Outperform | $13.00 |
| 2015-06-01 | Upgrade | Morgan Stanley | Underweight to Equal Weight | $5.00 to $10.00 |
| 2015-06-01 | Boost Price Target | Canaccord Genuity | Buy | $15.00 to $20.00 |
| 2015-05-14 | Reiterated Rating | Canaccord Genuity | Buy | $15.00 |
| 2015-05-06 | Initiated Coverage | Credit Suisse | Neutral | $10.00 |
| 2015-05-06 | Initiated Coverage | Credit Suisse Group AG | Neutral | $10.00 |
| 2015-04-28 | Reiterated Rating | William Blair | Outperform | |
| 2015-04-27 | Reiterated Rating | Canaccord Genuity | Buy | $10.00 to $15.00 |
| 2015-04-26 | Reiterated Rating | Cantor Fitzgerald | Buy | $12.00 |
| 2015-03-31 | Upgrade | Cantor Fitzgerald | Hold to Buy | $9.00 to $12.00 |
| 2015-02-06 | Upgrade | Oppenheimer | Market Perform to Outperform | $11.00 |
| 2014-12-22 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $13.00 to $6.00 |
| 2014-12-22 | Downgrade | Cantor Fitzgerald | Hold | $14.00 to $9.00 |
| 2014-12-22 | Lower Price Target | RBC Capital | Outperform | $18.00 to $11.00 |
| 2014-12-19 | Downgrade | Leerink Swann | Outperform to Market Perform | |
| 2014-12-19 | Downgrade | Jefferies Group | Buy to Hold | $20.00 to $7.00 |
| 2014-11-03 | Initiated Coverage | Cowen and Company | Market Perform | $8.50 |
| 2014-06-25 | Initiated Coverage | Morgan Stanley | Underweight | $10.00 |
| 2014-04-16 | Initiated Coverage | Canaccord Genuity | Buy to Buy | $20.00 |
| 2014-01-31 | Boost Price Target | Guggenheim | $14.00 to $15.00 | |
| 2013-11-11 | Downgrade | Morgan Stanley | Equal Weight to Underweight | $9.50 |
| 2013-11-08 | Lower Price Target | RBC Capital | Outperform | $22.00 to $18.00 |
| 2013-11-05 | Reiterated Rating | Chardan Capital | Buy | $21.00 |
| 2013-11-05 | Lower Price Target | Guggenheim | Neutral | $17.00 to $14.00 |
| 2013-11-05 | Downgrade | Stifel Nicolaus | Hold to Sell | |
| 2013-09-30 | Initiated Coverage | Chardan Capital | Buy | $21.00 |
| 2013-08-05 | Reiterated | Cantor Fitzgerald | Hold | $13 to $14 |
| 2013-08-02 | Reiterated | Cowen | Outperform | $20 |
| 2013-01-28 | Downgrade | Oppenheimer | Outperform to Perform | $28 |
| 2012-10-29 | Reiterated | Cantor Fitzgerald | Hold | $15 to $12 |
| 2012-09-27 | Initiated | UBS | Sell | $10 |
| 2012-06-14 | Initiated | Cantor Fitzgerald | Hold | $15 |
| 2011-04-08 | Upgrade | RBC Capital Mkts | Sector Perform to Outperform | $7 to $16 |
| 2011-03-01 | Reiterated | Brean Murray | Buy | $9 to $11 |
| 2010-04-15 | Reiterated | Morgan Joseph | Buy | $10 to $15 |
| 2010-04-15 | Reiterated | Canaccord Adams | Buy | $9.50 to $11.50 |
| 2010-01-27 | Initiated | Canaccord Adams | Buy | |
| 2009-10-08 | Initiated | Brean Murray | Buy | $14 |
| 2009-07-13 | Downgrade | Lazard Capital Mkts | Buy to Hold |
| 2016-06-08 | Reiterated Rating | Cantor Fitzgerald | Hold | |
| 2016-06-06 | Reiterated Rating | Cowen and Company | Hold | |
| 2016-05-19 | Reiterated Rating | RBC Capital | Sector Perform | $7.00 |
| 2016-05-19 | Reiterated Rating | Royal Bank Of Canada | Sector Perform | $7.00 |
| 2016-05-05 | Reiterated Rating | Morgan Stanley | Underweight | $9.00 to $5.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In IMGN 164 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| RA CAPITAL MANAGEMENT, LLC | 21.74M |
| BlackRock Inc. | 17.45M |
| Vanguard Group, Inc | 15.62M |
| STATE STREET CORP | 14.59M |
| DEERFIELD MANAGEMENT CO | 13.74M |
| WELLINGTON MANAGEMENT CO LLP | 10.01M |
| Redmile Group, LLC | 8.55M |
| ADAGE CAPITAL PARTNERS GP LLC | 7.90M |
| JENNISON ASSOCIATES LLC | 6.20M |
| Clearbridge Investments, LLC | 4.83M |
| MORGAN STANLEY | 4.74M |
| GEODE CAPITAL MANAGEMENT, LLC | 3.71M |
| MAVERICK CAPITAL LTD | 3.55M |
| TWO SIGMA ADVISERS, LLC | 3.01M |
| DEUTSCHE BANK AG\ | 3.01M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Enyedy Mark J Chief Executive Officer | 0.62% (532383) | FATE / IMGN / KERX / |
| Gregory Richard J. Executive VP & CSO | 0.28% (239094) | IMGN / |
| JUNIUS DANIEL M Chief Executive Officer | 0.22% (184987) | GLYC / IDXX / IMGN / VTAE / |
| Johnston David Brannon Chief Financial Officer | 0.21% (180690) | AVEO / IMGN / |
| BARROWS CRAIG Vice-President,General Counsel | 0.20% (168952) | IMGN / |
| Berkenblit Anna VP & Chief Medical Officer | 0.17% (144471) | IMGN / |
| LAMBERT JOHN Executive Vice President | 0.13% (110746) | IMGN / |
| Ryll Thomas VP, Technical Operations | 0.11% (96224) | IMGN / |
| Wingrove Theresa VP of Regulatory Affairs | 0.11% (90671) | IMGN / |
| Williams Peter J. VP, Business Development | 0.06% (50620) | IMGN / |
| Morris Charles Q Executive VP & CDO | 0.03% (27090) | IMGN / |
| Goldberg Mark Alan | 0.03% (23800) | BOLD / GEVA / GLYC / IDRA / IMGN / |
| PERRY GREGORY D Chief Financial Officer | 0.02% (18337) | AEGR / IMGN / KALA / QLTI / |
| MITCHELL DEAN J | 0.01% (10000) | IMGN / TBPH / XON / |
UM